← Leaderboards
Thomas F. Patterson
University Of Texas San Antonio
$4,803,300
Attributed
$4,803,300
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $9M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,909,953 · 4
By mechanism
U19$24,236,415 · 2
R01$3,673,538 · 2
Top collaborators
- Gabriel Alejandro De Erausquin5 shared
- Gabriela Gonzalez Aleman5 shared
- Mindy Katz5 shared
- Sudha Seshadri5 shared
Most similar at University Of Texas San Antonio
Same institution · by research overlap
- Chiung-Yu Hung$5,101,104
- Jose L. Lopez-Ribot$7,729,701
- Jieh-Juen Yu$1,366,846
Others in their field
Top investigators on “Epidemiology”
- David Heimbrook · Leidos Biomedical Research, Inc.$390,770,069
- George R Seage · Abt Associates, Inc.$299,251,523
- Jeffrey P Krischer · University Of South Florida$264,076,260
- Barbara Driver · Westat, Inc.$221,167,491
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$206,739,528
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
EpidemiologyAlzheimer&AposInfectionAntifungal AgentsCandida AlbicansCandidiasisSamplingProgramsFluconazoleResearch PersonnelCohortRisk FactorsAffectTexasAzole ResistanceIn VivoResistanceAfricanIn VitroAzolesCentral Nervous SystemFungal Drug ResistanceHigh RiskAids/Hiv Problem
Grant awards (21)
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimerâs disease in Ancestral and Admixed Populations$4,853,251
U19 · FY2025 · AG
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimerâs disease in Ancestral and Admixed Populations$806,739
U19 · FY2025 · AG
Relationship between in vitro antifungal resistance and in vivo response in coccidioidomycosis$271,400
U19 · FY2025 · AI · contact PI
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimerâs disease in Ancestral and Admixed Populations$110,683
U19 · FY2025 · AG
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimerâs disease in Ancestral and Admixed Populations$8,610,822
U19 · FY2024 · AG
Relationship between in vitro antifungal resistance and in vivo response in coccidioidomycosis$240,285
U19 · FY2024 · AI · contact PI
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimerâs disease in Ancestral and Admixed Populations$8,725,158
U19 · FY2023 · AG
Relationship between in vitro antifungal resistance and in vivo response in coccidioidomycosis$280,131
U19 · FY2023 · AI · contact PI
Relationship between in vitro antifungal resistance and in vivo response in coccidioidomycosis$337,946
U19 · FY2022 · AI · contact PI
Detection and Significance of Antifungal Resistance in Oropharyngeal Candidiasis$499,459
R01 · FY2010 · DE · contact PI
Detection and Significance of Antifungal Resistance in Oropharyngeal Candidiasis$491,969
R01 · FY2009 · DE · contact PI
Detection and Significance of Antifungal Resistance in Oropharyngeal Candidiasis$65,962
R01 · FY2009 · DE · contact PI
Detection and Significance of Antifungal Resistance in Oropharyngeal Candidiasis$488,352
R01 · FY2008 · DE · contact PI
Detection and Significance of Antifungal Resistance in Oropharyngeal Candidiasis$478,290
R01 · FY2007 · DE · contact PI
Detection and Significance of Antifungal Resistance in Oropharyngeal Candidiasis$474,494
R01 · FY2006 · DE · contact PI
FLUCONAZOLE RESISTANCE IN OROPHARYNGEAL CANDIDIASIS$258,265
R01 · FY2002 · DE
FLUCONAZOLE RESISTANCE IN OROPHARYNGEAL CANDIDIASIS$252,330
R01 · FY2001 · DE
FLUCONAZOLE RESISTANCE IN OROPHARYNGEAL CANDIDIASIS$100,000
R01 · FY2001 · DE
FLUCONAZOLE RESISTANCE IN OROPHARYNGEAL CANDIDIASIS$251,848
R01 · FY2000 · DE
Expression Analysis of Candida albicans$250,000
R01 · FY2000 · DE
FLUCONAZOLE RESISTANCE IN OROPHARYNGEAL CANDIDIASIS$62,569
R01 · FY2000 · DE